180 Wealth Advisors’s Edesa Biotech EDSA Stock Holding History

180 Wealth Advisors’s Portfolio EDSA Stock Details EDSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,857	Closed	-$156K	–	396
2021 Q3	$156K	Buy	2,857 +714	+33%	+$27.8K	0.03%	368
2021 Q2	$70K	Buy	+2,143	New	+$86.8K	0.02%	357

Other funds holding EDSA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

180 Wealth Advisors's EDSA Position: Q4 2021 in Review

180 Wealth Advisors sold out of Edesa Biotech (EDSA) in Q4 2021, closing a stake of 2,857 shares — an estimated $156K sold.

180 Wealth Advisors first reported a position in EDSA in Q2 2021 and held it in 2 quarters. The position peaked at $156K in Q3 2021. 25 funds tracked by Wall St. Rank hold EDSA as of Q4 2021.

180 Wealth Advisors reported no remaining Edesa Biotech position as of Q4 2021 after selling out during the quarter.
180 Wealth Advisors sold 2,857 Edesa Biotech shares in Q4 2021, an estimated $156K.
180 Wealth Advisors first reported a position in Edesa Biotech in Q2 2021 and held it in 2 quarters.
180 Wealth Advisors's Edesa Biotech position peaked at $156K in Q3 2021.
25 funds tracked by Wall St. Rank held Edesa Biotech as of Q4 2021.

Based on 180 Wealth Advisors's 13F filing for Q4 2021, filed 26 Jan 2022.